Painreform Ltd (PRFX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Painreform Ltd (PRFX) has a cash flow conversion efficiency ratio of -0.117x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-991.00K) by net assets ($8.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Painreform Ltd to measure how much of total assets are equity-financed.
Painreform Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Painreform Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PRFX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Painreform Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Painreform Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coppermoly Ltd
AU:COY
|
-0.136x |
|
Knights Group Holdings plc
LSE:KGH
|
0.151x |
|
Nexera Energy Inc
V:NGY
|
-0.007x |
|
Radaan Mediaworks India Limited
NSE:RADAAN
|
0.196x |
|
CFI-Compagnie Foncière Internationale
PA:CFI
|
0.135x |
|
Nordon Indústrias Metalúrgicas S/A
SA:NORD3
|
0.017x |
|
RIVER TECH EO -005
F:9YQ
|
N/A |
|
Kulthorn Kirby Public Company Limited
BK:KKC
|
0.049x |
Annual Cash Flow Conversion Efficiency for Painreform Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Painreform Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see PRFX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.82 Million | $-12.62 Million | -6.919x | -649.96% |
| 2023-12-31 | $7.24 Million | $-6.68 Million | -0.923x | -57.43% |
| 2022-12-31 | $11.02 Million | $-6.46 Million | -0.586x | -61.72% |
| 2021-12-31 | $18.08 Million | $-6.55 Million | -0.362x | -135.56% |
| 2020-12-31 | $16.62 Million | $-2.56 Million | -0.154x | -242.03% |
| 2019-12-31 | $-5.62 Million | $-609.00K | 0.108x | -23.97% |
| 2018-12-31 | $-4.46 Million | $-635.00K | 0.142x | -40.57% |
| 2017-12-31 | $-3.63 Million | $-870.00K | 0.240x | -- |
About Painreform Ltd
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinica… Read more